1[1]Wall ME, Wani MC, Cook CE, et al. Antitumor agent I. The isolation and structure of Camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata [J]. J Amer Chem Soc, 1966,88(16):3888-3890.
2[2]O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration [J]. Eur J Cancer, 1998,34(10):1500-1508.
3[3]Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin [J]. Ann N Y Acad Sci, 2000,922:1-10.
4[4]Slichenmyer WJ, Rowinsky EK, Donehower RC. The current status of camptothecin analogues as antitumor agents [J]. J Nat Cancer Inst, 85(4):271-291.
5[5]Saijo N. Clinical trials of irinotecan hydrochloride in Japan [J]. Ann N Y Acad Sci, 1996,803:292-305.
6[6]Broom C. Clinical studies of Topotecan [J]. Ann N Y Acad Sci, 1996,803:264-271.
7[7]Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8 951 f, exhibits potent antitumor activity against human tumors in vitro and in vivo [J]. Jpn J Cancer Res, 1995,86:(8)776-782.
8[8]Luzzio MJ, Besterman JM, Emerson DL, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I [J]. J Med Chem, 1995,38(3):395-401.
9[9]Lee JH, Lee JM, Lim KH, et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative [J]. Ann NY Acad Sci, 2000,922:324-325.
10[10]Verschraegen CF, Gupta E, Loyer E et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin patents with refractory epithelial ovarian, tubal or peritoneal cancer [J]. Anticancer Drugs, 1999,10(4):375-383.
